From fibro/adipogenic progenitors to adipocytes: Understanding adipogenesis in muscle degeneration for disease modulation.
Villalobos E., Mehra P., Diaz-Manera J.
Narrative Review, published in J Physiol (2025) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Narrative Review
- Journal
- J Physiol (2025)
- Country
- England
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 40846464
- PMCID
- PMC12487600
- DOI
- 10.1113/JP288924
- Citations
- 2
Abstract (original English)
Fibro/adipogenic progenitors (FAPs) are muscle-resident stem cells essential for muscle regeneration because of their ability to differentiate into adipocytes and fibroblasts. This differentiation contributes to tissue remodelling and is implicated in the accumulation of fat and fibrotic tissue seen in neuromuscular, cardiovascular and degenerative diseases. FAPs also interact with other muscle cells and modulate inflammation, playing a central role in muscle degeneration across various disease contexts. This review summarises current knowledge on FAP adipogenic differentiation in muscle degeneration and regeneration, with a focus on cardiovascular and neuromuscular diseases, which share common features of impaired muscle remodelling. We discuss established methods for culturing, maintaining, and differentiating FAPs in vitro to support future research. Additionally, we examine FAP subpopulations, key signalling pathways and pharmacological agents influencing FAP differentiation into adipocytes. Understanding these mechanisms offers promising avenues for developing therapeutic strategies to restore muscle homeostasis and slow down pathological muscle remodelling.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.